RESUMO
The term "emerging technology" (ET) is used extensively, and there are numerous definitions offered, but to our knowledge, none specifically encompass the field of laboratory medicine. An ET definition that incorporates the overarching IFCC aim of "Advancing excellence in laboratory medicine to support healthcare worldwide" would clarify discussions. We discuss key aspects of the term "emerging technology(ies)" as it applies to laboratory medicine with a view to laying the foundations for a practical definition for the profession and propose the definition of an ET as "An analytical method or device that by virtue of its stage of development, translation into broad routine clinical practice, or geographical adoption and implementation has the potential to add value to clinical diagnostics".
Assuntos
Atenção à Saúde , LaboratóriosRESUMO
An emerging technology (ET) for laboratory medicine can be defined as an analytical method (including biomarkers) or device (software, applications, and algorithms) that by its stage of development, translation into broad routine clinical practice, or geographical adoption and implementation has the potential to add value to clinical diagnostics. Considering the laboratory medicine-specific definition, this document examines eight key tools, encompassing clinical, analytical, operational, and financial aspects, used throughout the life cycle of ET implementation. The tools provide a systematic approach starting with identifying the unmet need or identifying opportunities for improvement (Tool 1), forecasting (Tool 2), technology readiness assessment (Tool 3), health technology assessment (Tool 4), organizational impact map (Tool 5), change management (Tool 6), total pathway to method evaluation checklist (Tool 7), and green procurement (Tool 8). Whilst there are differences in clinical priorities between different settings, the use of this set of tools will help support the overall quality and sustainability of the emerging technology implementation.
Assuntos
Tecnologia Biomédica , Ciência de Laboratório Médico , Previsões , Ciência de Laboratório Médico/tendênciasRESUMO
Predictions about the future of laboratory medicine have had a mixed success, and in some instances they have been overambitious and incorrectly assessed the future impact of emerging technologies. Current predictions suggest a more highly automated and connected future for diagnostic testing. The central laboratory of the future may be dominated by more robotics and more connectivity in order to take advantage of the benefits of the Internet of Things and artificial intelligence (AI)-based systems (e.g. decision support software and imaging analytics). For point-of-care testing, mobile health (mHealth) may be in the ascendancy driven by healthcare initiatives from technology companies such as Amazon, Apple, Facebook, Google, IBM, Microsoft and Uber.
Assuntos
Inteligência Artificial , Ciência de Laboratório Médico , Testes Imediatos , Telemedicina , HumanosRESUMO
BACKGROUND: Point-of-care technology (POCT) provides actionable information at the site of care to allow rapid clinical decision-making. With healthcare emphasis shifting toward precision medicine, population health, and chronic disease management, the potential impact of POCT continues to grow, and several prominent POCT trends have emerged or strengthened in the last decade. CONTENT: This review summarizes current and emerging trends in POCT, including technologies approved or cleared by the Food and Drug Administration or in development. Technologies included have either impacted existing clinical diagnostics applications (e.g., continuous monitoring and targeted nucleic acid testing) or are likely to impact diagnostics delivery in the near future. The focus is limited to in vitro diagnostics applications, although in some sections, technologies beyond in vitro diagnostics are also included given the commonalities (e.g., ultrasound plug-ins for smart phones). For technologies in development (e.g., wearables, noninvasive testing, mass spectrometry and nuclear magnetic resonance, paper-based diagnostics, nanopore-based devices, and digital microfluidics), we also discuss their potential clinical applications and provide perspectives on strategies beyond technological and analytical proof of concept, with the end goal of clinical implementation and impact. SUMMARY: The field of POCT has witnessed strong growth over the past decade, as evidenced by new clinical or consumer products or research and development directions. Combined with the appropriate strategies for clinical needs assessment, validation, and implementation, these and future POCTs may significantly impact care delivery and associated outcomes and costs.
Assuntos
Tecnologia Biomédica/tendências , Tomada de Decisão Clínica/métodos , Sistemas Automatizados de Assistência Junto ao Leito/tendências , Tecnologia Biomédica/instrumentação , Humanos , Técnicas de Diagnóstico Molecular/instrumentação , Técnicas de Diagnóstico Molecular/tendências , Medicina de Precisão/instrumentação , Medicina de Precisão/tendências , Telemedicina/instrumentação , Telemedicina/tendênciasRESUMO
Important and emerging trends at the interface of luminescence, nucleic acids and nanotechnology are: (i) the conventional luminescence labeling of nucleic acid nanostructures (e.g. DNA tetrahedron); (ii) the labeling of bulk nucleic acids (e.g. single-stranded DNA, double-stranded DNA) with nanostructured luminescent labels (e.g. copper nanoclusters); and (iii) the labeling of nucleic acid nanostructures (e.g. origami DNA) with nanostructured luminescent labels (e.g. silver nanoclusters). This review surveys recent advances in these three different approaches to the generation of nanostructured luminescently labeled nucleic acids, and includes both direct and indirect labeling methods.
Assuntos
Luminescência , Nanoestruturas/química , Ácidos Nucleicos/químicaRESUMO
BACKGROUND: Reporting clinically actionable incidental genetic findings in the course of clinical exome testing is recommended by the American College of Medical Genetics and Genomics (ACMG). However, the performance of clinical exome methods for reporting small subsets of genes has not been previously reported. METHODS: In this study, 57 exome data sets performed as clinical (n = 12) or research (n = 45) tests were retrospectively analyzed. Exome sequencing data was examined for adequacy in the detection of potentially pathogenic variant locations in the 56 genes described in the ACMG incidental findings recommendation. All exons of the 56 genes were examined for adequacy of sequencing coverage. In addition, nucleotide positions annotated in HGMD (Human Gene Mutation Database) were examined. RESULTS: The 56 ACMG genes have 18 336 nucleotide variants annotated in HGMD. None of the 57 exome data sets possessed a HGMD variant. The clinical exome test had inadequate coverage for >50% of HGMD variant locations in 7 genes. Six exons from 6 different genes had consistent failure across all 3 test methods; these exons had high GC content (76%-84%). CONCLUSIONS: The use of clinical exome sequencing for the interpretation and reporting of subsets of genes requires recognition of the substantial possibility of inadequate depth and breadth of sequencing coverage at clinically relevant locations. Inadequate depth of coverage may contribute to false-negative clinical exome results.
Assuntos
DNA/genética , Exoma/genética , Achados Incidentais , Técnicas de Diagnóstico Molecular/métodos , Análise de Sequência de DNA/métodos , Bases de Dados Genéticas , Variação Genética , Humanos , Estudos RetrospectivosRESUMO
The joint 5th Pan Arab Human Genetics conference and 2013 Golden Helix Symposium, "Genomics into Healthcare" was coorganized by the Center for Arab Genomic Studies (http://www.cags.org.ae) in collaboration with the Golden Helix Foundation (http://www.goldenhelix.org) in Dubai, United Arab Emirates from 17 to 19 November, 2013. The meeting was attended by over 900 participants, doctors and biomedical students from over 50 countries and was organized into a series of nine themed sessions that covered cancer genomics and epigenetics, genomic and epigenetic studies, genomics of blood and metabolic disorders, cytogenetic diagnosis and molecular profiling, next-generation sequencing, consanguinity and hereditary diseases, clinical genomics, clinical applications of pharmacogenomics, and genomics in public health.
Assuntos
Atenção à Saúde , Epigênese Genética , Genética Médica , Genômica , Citogenética , Bases de Dados Genéticas , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Emirados Árabes UnidosRESUMO
Chemiluminescent reactions have found application in a number of commercial point-of-care and on-site testing devices. Notable examples include allergy tests (e.g., MASTpette, OPTIGEN® systems), flu tests (e.g., ZstatFlu®-II), cartridge-based immunoassay systems (FastPack® IP System, PATHFAST®), forensic tests for bloodstains, portable analyzers for biochip array assays (Evidence MultiStat), water quality tests (Eclox), air pollutants (e.g., oxides of nitrogen), and handheld devices for detecting explosives (e.g., E3500 Chemilux®). Many other point-of-care or on-site testing devices with a chemiluminescent end point have been devised on the basis of a variety of formats (e.g., cuvette, cassette, dipstick, test strip, microchip), but most have not progressed beyond a proof-of-principle or prototype stage.
Assuntos
Técnicas e Procedimentos Diagnósticos/instrumentação , Monitoramento Ambiental/instrumentação , Medições Luminescentes/instrumentação , Sistemas Automatizados de Assistência Junto ao Leito/tendências , Técnicas e Procedimentos Diagnósticos/tendências , Monitoramento Ambiental/métodos , Humanos , Medições Luminescentes/economia , Medições Luminescentes/métodos , Medições Luminescentes/tendências , Sistemas Automatizados de Assistência Junto ao Leito/economiaRESUMO
Commercial chemiluminescent reagents emit across a broad portion of the electromagnetic spectrum (400-500 nm). A challenge to the use of chemiluminescence to monitor biological processes is the presence of interfering substances in the biological optical window. In the present study, longer wavelength emitting fluorophores (the organic dyes Alexa 568 and Alexa 647), and a semiconductor nanoparticle (QDOT800) were used to red-shift the emission from commercially available 1,2-dioxetane-based chemiluminescent substrate reactions. By adding non-conjugated fluorescent emitters into chemiluminescent reaction mixtures, an emission peak occurred at the predicted wavelength of the fluorescent emitter. The excitation and emission from QDOT800 was preserved in the presence of a 100 µm-thick glass barrier separating it from the chemiluminescent reaction components. The maximum tissue phantom penetration by QDOT800 emission was 8.5 mm; in comparison, the native chemiluminescent emission at 500 nm was unable to penetrate the thinnest tissue phantom of 2.5 mm. The described method for red-shifted emissions from chemiluminescent reactions does not require direct interaction between the chemiluminescent reaction and the fluorescent emitters. This suggests that the mechanism of chemiluminescent excitation of fluorophores and QDOT800 is not exclusive to chemiluminescence resonance energy transfer or sensitized chemiluminescence, but rather by broad energization from the native chemiluminescent emission.
Assuntos
Compostos Heterocíclicos/química , Luminescência , Corantes/química , Compostos Heterocíclicos com 1 Anel , Nanopartículas/química , Semicondutores , Espectrofotometria InfravermelhoAssuntos
Testes Genéticos/ética , Testes Genéticos/métodos , Participação da Comunidade/métodos , Autoavaliação Diagnóstica , Europa (Continente) , Testes Genéticos/economia , Acessibilidade aos Serviços de Saúde/ética , Humanos , América do Norte , Farmacêuticos , Relações Médico-Paciente/ética , Relações Profissional-Paciente/ética , Kit de Reagentes para Diagnóstico/economia , Kit de Reagentes para Diagnóstico/ética , Kit de Reagentes para Diagnóstico/provisão & distribuiçãoRESUMO
Background: Eponyms are ubiquitous in dermatology; however, their usage trends have not been studied. Objective: To characterize the usage of eponyms in dermatology from 1880 to 2020. Methods: Candidate eponyms were collected from a textbook and an online resource. A subset of these eponyms was deemed to be dermatology-focused by a panel of experienced dermatologists. Python scripts were used to permute eponyms into multiple variations and automatically search PubMed using BioPython's Entrez library. Results: The dermatologist panel designated 373 of 529 candidate eponyms as dermatology-focused. These eponyms were permuted into 3159 variations and searched in PubMed. The highest occurring dermatology-focused eponyms (DFEs) in the year 2020 included Leishmania, Behçet syndrome, Kaposi sarcoma, Langerhans cell histiocytosis, and Mohs surgery. Increased DFE usage in the general medical literature parallels the overall increase in the use of other eponyms in the medical literature. However, in the most cited dermatology journals, DFE usage did not increase in the past decade. There were several eponyms with decreased usage. Limitations: This study is limited to the publications in PubMed; only titles and abstracts could be queried. Conclusion: DFEs are increasing in usage in the general medical literature, but the usage of eponyms in the most cited dermatology journals has plateaued.
RESUMO
BACKGROUND: This review was written as part of the celebration of the International Year of Chemistry 2011. CONTENT: In this review we provide a chronicle of the history of clinical chemistry, with a focus on North America. We outline major methodological advances and trace the development of professional societies and journals dedicated to clinical chemistry. This review also serves as a guide to reference materials for those interested in the history of clinical chemistry. The various resources available, in sound recordings, videos, moving images, image and document archives, museums, and websites dedicated to diagnostic company timelines, are surveyed. SUMMARY: These resources provide a map of how the medical subspecialty of clinical chemistry arrived at its present state. This information will undoubtedly help visionaries to determine in which direction clinical chemistry will move in the future.
Assuntos
Arquivos/história , Química Clínica/história , História do Século XX , História do Século XXI , Museus/históriaRESUMO
BACKGROUND: Several companies offer direct-to-consumer (DTC) genetic testing to evaluate ancestry and wellness. Massive-scale testing of thousands of single-nucleotide polymorphisms (SNPs) is not error free, and such errors could translate into misclassification of risk and produce a false sense of security or unnecessary anxiety in an individual. We evaluated 3 DTC services and a genomics service that are based on DNA microarray or solution genotyping with hydrolysis probes (TaqMan® analysis) and compared the test results obtained for the same individual. METHODS: We evaluated the results from 3 DTC services (23andMe, deCODEme, Navigenics) and a genomics-analysis service (Expression Analysis). RESULTS: The concordance rates between the services for SNP data were >99.6%; however, there were some marked differences in the relative disease risks assigned by the DTC services (e.g., for rheumatoid arthritis, the range of relative risk was 0.9-1.85). A possible reason for this difference is that different SNPs were used to calculate risk for the same disease. The reference population also had an influence on the relative disease risk. CONCLUSIONS: Our study revealed excellent concordance between the results of SNP analyses obtained from different companies with different platforms, but we noted a disparity in the data for risk, owing to both differences in the SNPs used in the calculation and the reference population used. The larger issues of the utility of the information and the need for risk data that match the user's ethnicity remain, however.
Assuntos
Informação de Saúde ao Consumidor , Testes Genéticos , Análise de Sequência com Séries de Oligonucleotídeos , DNA/genética , Predisposição Genética para Doença , Testes Genéticos/economia , Testes Genéticos/métodos , Testes Genéticos/normas , Humanos , Marketing de Serviços de Saúde , Análise de Sequência com Séries de Oligonucleotídeos/economia , Análise de Sequência com Séries de Oligonucleotídeos/métodos , Análise de Sequência com Séries de Oligonucleotídeos/normas , Polimorfismo de Nucleotídeo Único , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeRESUMO
BACKGROUND: In the 1880s, concern over the inconvenience of hazardous chemical solutions used for bedside urinalysis sparked an interest in the development of dry reagents for a range of common urine tests. CONTENT: This article examines the history of Dr Pavy's Pellets and Dr Oliver's Papers, 2 different dry reagent systems developed in the 1880s for bedside urine testing. It sets these developments in the context of the earlier dry chemistry work (e.g., indicator papers) and the subsequent work that led to modern day reagent tablets and dipstick devices. SUMMARY: Tests based on dry reagents can be traced back to the 1st century, but active development, in the form of indicator papers, dates from the 1600s. In the 1880s, spurred by dissatisfaction with liquid-based bedside urine testing among clinicians, Dr Frederick William Pavy and Dr George Oliver developed dry reagent tests, based on pellets (Dr Pavy's Pellets) and chemically impregnated papers (Dr Oliver's Papers) for urine sugar and urine albumin. These reagents were commercialized by a number of companies and provided in convenient cases (Physician's Pocket Reagent Case). Eventually, these tests lost popularity and were replaced by the type of tablets and dipsticks developed by both Eli Lilly, and the Ames Division of Miles Laboratories (subsequently Bayer, and currently Siemens Healthineers) during the 1940s and 1950s.